Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$143.82
-2.7%
$210.88
$143.40
▼
$479.79
$19.26B0.421.62 million shs2.32 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$121.40
-2.1%
$138.67
$77.00
▼
$160.81
$7.92B1.21708,025 shs600,727 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$38.60
-0.9%
$37.22
$19.96
▼
$42.50
$27.97B1.236.57 million shs3.97 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$554.73
-0.8%
$548.85
$455.63
▼
$614.23
$23.63B0.49551,296 shs355,162 shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-1.06%-5.64%-35.93%-37.42%-67.92%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-2.47%-7.71%-10.12%-19.63%+45.68%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+0.59%-2.58%+11.57%+7.33%+91.54%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
-3.16%-5.77%+0.94%+8.96%+17.32%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$143.82
-2.7%
$210.88
$143.40
▼
$479.79
$19.26B0.421.62 million shs2.32 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$121.40
-2.1%
$138.67
$77.00
▼
$160.81
$7.92B1.21708,025 shs600,727 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$38.60
-0.9%
$37.22
$19.96
▼
$42.50
$27.97B1.236.57 million shs3.97 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$554.73
-0.8%
$548.85
$455.63
▼
$614.23
$23.63B0.49551,296 shs355,162 shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-1.06%-5.64%-35.93%-37.42%-67.92%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-2.47%-7.71%-10.12%-19.63%+45.68%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+0.59%-2.58%+11.57%+7.33%+91.54%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
-3.16%-5.77%+0.94%+8.96%+17.32%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.63
Moderate Buy$287.70100.04% Upside
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
3.06
Buy$166.6737.29% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.79
Moderate Buy$46.8221.30% Upside
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
2.69
Moderate Buy$676.4021.93% Upside

Current Analyst Ratings Breakdown

Latest PTGX, ALNY, ROIV, and UTHR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/20/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Boost Price TargetOutperform$292.00 ➝ $293.00
11/18/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
UpgradeBuy (B-) ➝ Buy (B)
11/18/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
DowngradeNeutral
11/18/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Set Price Target$254.00
11/17/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Reiterated RatingSell (D-)
11/17/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Lower Price TargetNeutral$290.00 ➝ $205.00
11/17/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Lower Price TargetBuy$455.00 ➝ $250.00
11/16/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Boost Price TargetBuy$46.00 ➝ $48.00
11/10/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Boost Price TargetBuy$47.00 ➝ $48.00
11/9/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
DowngradeBuy (B-) ➝ Hold (C+)
11/9/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Reiterated RatingOutperform
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$3.71B5.19$2.69 per share53.43$26.91 per share5.34
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$46.02M172.18N/AN/A$16.62 per share7.30
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$8.26M3,385.61N/AN/A$6.34 per share6.09
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$3.19B7.41$31.70 per share17.50$147.36 per share3.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$313.75M$19.267.4717.67N/A52.85%155.33%44.81%N/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$130.15M$4.7225.7291.28N/A62.04%42.83%40.29%N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$299.77M-$0.63N/AN/AN/A-838.21%-22.03%-20.55%2/5/2027 (Estimated)
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$1.33B$26.5020.9317.313.8438.61%19.18%17.07%N/A

Latest PTGX, ALNY, ROIV, and UTHR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$2.50$3.07+$0.57$3.07$238.49 million$274.41 million
11/4/2026Q3 2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$6.01$5.71-$0.30$5.71$781.14 million$832.50 million
10/29/2026Q3 2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$1.66$16.26+$14.60$15.72$1.43 billion$1.46 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.18
2.48
2.43
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/A
19.85
19.85
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
15.56
15.56
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/A
4.61
4.29

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
98.63%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
94.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,770133.94 million132.79 millionOptionable
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
14165.27 million61.88 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
721724.56 million660.80 millionOptionable
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
1,40042.59 million38.93 millionOptionable

Recent News About These Companies

United Therapeutics Reports First Pig Kidney Transplant in Trial
United Therapeutics (NASDAQ:UTHR) CEO Sells $5,583,530.00 in Stock
United Therapeutics (UTHR) Gets a Hold from Morgan Stanley
FY2026 Earnings Forecast for UTHR Issued By HC Wainwright
Analysts Issue Forecasts for UTHR FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$143.82 -4.00 (-2.71%)
Closing price 04:00 PM Eastern
Extended Trading
$144.56 +0.74 (+0.51%)
As of 05:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Protagonist Therapeutics stock logo

Protagonist Therapeutics NASDAQ:PTGX

$121.40 -2.62 (-2.11%)
Closing price 04:00 PM Eastern
Extended Trading
$121.46 +0.06 (+0.05%)
As of 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$38.60 -0.36 (-0.93%)
Closing price 03:58 PM Eastern
Extended Trading
$38.65 +0.05 (+0.14%)
As of 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

United Therapeutics stock logo

United Therapeutics NASDAQ:UTHR

$554.73 -4.37 (-0.78%)
Closing price 04:00 PM Eastern
Extended Trading
$550.30 -4.43 (-0.80%)
As of 05:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.